Peptides, FDA’s Pharmacy Compounding Advisory Committee, and the Future of FDA Drug Approval
In the authors' words
This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.
Main result
This Viewpoint discusses the US Food and Drug Administration’s (FDA) Pharmacy Compounding Advisory Committee’s recommendation to add 7 peptides to the compounding 503A Bulks List and the profound threat that compounding these peptides could represent to the drug-approval process and patients.
Appeared: Wednesday, October 28. JAMA. Peer-reviewed journal.